Advertisement Pharmaceutical Business review - Page 95 of 5266 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
March 30, 2026

Novo Nordisk receives FDA approval for basal insulin Awiqli

Novo Nordisk has secured the US Food and Drug Administration (FDA) approval for Awiqli (insulin icodec-abae) injection 700 units/mL, a basal insulin for adults with type 2 diabetes (T2D).

The clinical trials assessed once-weekly Awiqli with mealtime insulin, oral anti-diabetic agents, and GLP-1 receptor agonists. Credit: Andrzej Rostek / Shutterstock.com.